Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

The U.S. Department of Defense Prostate Cancer Research Program has awarded the Data Science Award and a $1.2 million grant to researchers Charles Gaber, Natalie Reizine, Todd Lee, Lucia Petito, and Jessica Islam.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

July 11, 2025

Vol.51 No.27

In Brief

UVA Cancer Center expands prostate cancer awareness initiative

In recognition of Men’s Health Month, UVA Cancer Center is expanding “Stay in the Game,” a community-centered program to raise awareness across Virginia about prostate cancer and the importance of early screening.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.

June 06, 2025

Vol.51 No.22

Drugs & Targets

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

FDA approved the oral androgen receptor inhibitor Nubeqa (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer, which is also known as metastatic hormone-sensitive prostate cancer.

June 06, 2025

Vol.51 No.22

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

YOU MAY BE INTERESTED IN

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

UVA Cancer Center expands prostate cancer awareness initiative

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

Renew today!

Subscriber content

Never miss an issue!

Login